We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Celsion Announces ThermoDox® Preclinical Data Publication and Presentations at Upcoming Scientific Conferences

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Celsion Corporation has announced the publication of data highlighting the preclinical efficacy for ThermoDox® with High Intensity Focused Ultrasound (HIFU) as well as the presentation of related research abstracts at two upcoming medical conferences.

The article, titled "Localized drug release using MRI-controlled focused ultrasound" by lead author Robert Staruch from Centre for Research in Image-Guided Therapeutics, Sunnybrook Health Sciences Centre, in Toronto, Canada, will be published in the March 2011 issue of the International Journal of Hyperthermia.

The late-breaking abstracts will be presented at both the Annual Meetings of the Society of Thermal Medicine (STM) and International Society of Therapeutic Ultrasound (ISTU). The STM Annual Meeting will be held on April 29 - May 2, 2011 in New Orleans, LA, and the ISTU Annual Meeting will be held on April 11-13, 2011 in New York City.

The publication and abstracts establish proof of concept, rationale and support for future clinical studies combining ThermoDox® with MR-guided HIFU in the treatment of certain cancers. Celsion is developing the combination of ThermoDox® and HIFU through a joint research agreement with Philips Healthcare, a division of Royal Philips Electronics.

Celsion and Philips have submitted their preclinical findings with a request to initiate a clinical program in metastatic bone cancer to the U.S. Food and Drug Administration. The companies expect to initiate clinical studies later in 2011.

"Our preclinical research has shown an impressive ability to concentrate doxorubicin in tissue heated by Philips' non-invasive, MR-Guided HIFU technology, thus expanding the area of treatment in a targeted manner," said Michael H. Tardugno, Celsion's President and Chief Executive Officer.

Tardugno continued, "The combination of ThermoDox® and HIFU is a very promising development pathway with the potential to fill a significant gap between surgery and systemic chemotherapies in the treatment of certain cancers. These studies, conducted at leading research centers in the U.S., Canada and Europe, provide further support for our continued investment in expanding the oncology indications that can be addressed by ThermoDox®."

Dr. Nicholas Borys, Chief Medical Officer at Celsion Corporation, commented, "Both the academic and medical communities have been very supportive of targeted drug delivery applications using MR-guided HIFU. We are excited to enter the clinic later this year and treat patients with this innovative combination therapy."